Evaluation of combined mild hypothermia and magnesium as a neuroprotective therapy following cerebral ischaemia/stroke

亚低温联合镁作为脑缺血/中风后神经保护疗法的评价

• 批准号: nhmrc : 458643
• 负责人: A/Pr Bruno Meloni
• 金额: $ 20.69万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/evaluation-combined-mild-cerebral-ischaemiastroke/97146
• 关键词: Evaluation; combined; mild; hypothermia; magnesium

Stroke-cerebral ischaemia affects over 50,000 Australians every year and is Australia's leading single cause of disability and third greatest cause of death after heart disease. About 25% of people who suffer a stroke die within one month while most survivors are disabled because of impaired speech, memory, thought processes, vision, balance, or motor control of the limbs (paralysis). The direct and indirect cost of stroke-cerebral ischaemia to the Australian community is over $2 billion annually. The ability to inhibit or limit brain damage once a stroke has occurred will reduce the devastating effects of stroke to patients and the Australian community. Despite decades of research, there is no totally satisfactory drug that directly inhibits brain damage following stroke; the search for new treatments is paramount. A stroke occurs when there is a reduced blood supply to the entire brain (global cerebral ischaemia; eg. cardiac arrest, closed head injury) or to a specific region of the brain, usually as a result of a blockage in a brain artery (focal cerebral ischaemia or thrombo-embolic stroke). This project will evaluate the efficacy of combined magnesium and mild hypothermia (35) treatment protocols to reduce brain damage in animal models of focal and global cerebral ischaemia. This work stems from our recent data showing for the first time that magnesium is only neuroprotective in animals following cerebral ischaemia when present with hypothermia. Thus our data indicates that magnesium, when combined with hypothermia is an effective stroke therapy. Moreover treatment with magnesium-mild hypothermia has several attractions. Both are likely to have multiple mechanisms of action, are cheap to administer and safe. Importantly, the experimental findings from this project will enable better design of future clinical trials to test the efficacy of combined magnesium-modest hypothermia to improve patient outcome following stroke.

中风-脑缺血每年影响超过50，000名澳大利亚人，是澳大利亚残疾的主要单一原因，也是仅次于心脏病的第三大死亡原因。大约25%的中风患者在一个月内死亡，而大多数幸存者由于言语、记忆、思维过程、视力、平衡或肢体运动控制（瘫痪）受损而残疾。中风-脑缺血给澳大利亚社区造成的直接和间接费用每年超过20亿美元。一旦中风发生，抑制或限制脑损伤的能力将减少中风对患者和澳大利亚社区的破坏性影响。尽管经过数十年的研究，仍然没有完全令人满意的药物可以直接抑制中风后的脑损伤;寻找新的治疗方法至关重要。当整个大脑的血液供应减少时，就会发生中风（全脑缺血;例如，心脏骤停、闭合性头部损伤）或脑的特定区域，通常是由于脑动脉阻塞（局灶性脑缺血或血栓栓塞性中风）。该项目将评估镁和轻度低温（35）联合治疗方案在局灶性和全脑缺血动物模型中减少脑损伤的疗效。这项工作源于我们最近的数据首次表明，镁是唯一的神经保护动物脑缺血时，目前与低温。因此，我们的数据表明，镁，当结合低温是一种有效的中风治疗。此外，镁-轻度低温治疗有几个吸引人的地方。两者都可能有多种作用机制，管理成本低，安全。重要的是，该项目的实验结果将使未来的临床试验能够更好地设计，以测试镁-适度低温联合治疗改善卒中后患者预后的疗效。